• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DRD3 Gene Record

  • Summary
  • Interactions
  • Claims
  • DRD3 1814 Druggable Genome

    Alternate Names:

    1814
    DOPAMINE RECEPTOR D3
    DRD3
    D3DR
    ETM1
    FET1
    126451
    3024
    ENSG00000151577
    OTTHUMG00000159334
    D(3) DOPAMINE RECEPTOR. [SOURCE:UNIPROT/SWISSPROT;ACC:P35462]
    P35462
    D(3) DOPAMINE RECEPTOR
    DRD3_HUMAN
    Dopamine D3 receptor
    PA27479
    D3R
    T02551

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Name GPCR, rhodopsin-like, 7TM
    Interpro Acc IPR000276
    Interpro Type Family
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Uniprot Evidence 1: Evidence at protein level
    Human Readable Name G PROTEIN COUPLED RECEPTOR
    Uniprot Status Swiss-Prot
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin
    Transmembrane Helix Count 6
    Target Main Class Receptors
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    G PROTEIN COUPLED RECEPTOR
    DRUGGABLE GENOME

    Publications:

    Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol
    Damasceno Dos Santos EU et al., 2019, Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease., J Clin Pharmacol
    Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
    Koller et al., 1998, Mechanism of action of dopaminergic agents in Parkinson's disease., Neurology
    Onofrj et al., 2008, An expert opinion on safinamide in Parkinson's disease., Expert Opin Investig Drugs
    Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Cabaleiro T et al., 2015, Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects., Int Clin Psychopharmacol
    Vernaleken I et al., 2010, Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas., Int J Neuropsychopharmacol
    Bressan RA et al., 2003, Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study., J Clin Psychopharmacol
    Rosenzweig et al., 2002, A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., Hum Psychopharmacol
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Horacek et al., 2006, Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia., CNS Drugs
    George et al., 2013, Newer antipsychotics and upcoming molecules for schizophrenia., Eur. J. Clin. Pharmacol.
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J
    Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
    Megens et al., 1994, Survey on the pharmacodynamics of the new antipsychotic risperidone., Psychopharmacology (Berl.)
    Freedman et al., 1994, Expression and pharmacological characterization of the human D3 dopamine receptor., J. Pharmacol. Exp. Ther.
    Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem
    Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
    Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Shill HA et al., 2009, Update on ropinirole in the treatment of Parkinson's disease., Neuropsychiatr Dis Treat
    Nashatizadeh MM et al., 2009, A review of ropinirole prolonged release in Parkinson's disease., Clin Interv Aging
    Adams DH et al., 2008, Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder., Hum Psychopharmacol
    Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Chernoloz O et al., 2012, Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain., J Psychiatry Neurosci
    Dooley M et al., 1998, Pramipexole. A review of its use in the management of early and advanced Parkinson's disease., Drugs Aging
    Piercey MF, 1998, Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease., Clin Neuropharmacol
    Merlino G et al., 2008, Clinical experience with pramipexole in the treatment of restless legs syndrome., Expert Opin Drug Metab Toxicol
    Kessler et al., 2005, Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol., Neuropsychopharmacology
    Malmberg et al., 1998, Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding., J. Pharmacol. Exp. Ther.
    Tuppurainen et al., 2009, Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine., Psychiatry Clin. Neurosci.
    Tadori et al., 2008, Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors., Eur. J. Pharmacol.
    Hwang R et al., 2011, Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response., Pharmacogenomics
    Hwang R et al., 2010, Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant., Pharmacogenomics J
    Collo et al., 2008, Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation., Eur. J. Neurosci.
    Lipina et al., [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]., Zh Vyssh Nerv Deiat Im I P Pavlova
    Newman AH et al., 2012, Molecular determinants of selectivity and efficacy at the dopamine D3 receptor., J Med Chem
    Green et al., 2004, Focus on levomepromazine., Curr Med Res Opin
    Fux et al., 1991, A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia., Isr J Psychiatry Relat Sci
    Burstein et al., 2005, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist., J. Pharmacol. Exp. Ther.
    Citrome, 2013, Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability., Expert Opin Drug Metab Toxicol
    LeWitt PA, 2004, Subcutaneously administered apomorphine: pharmacokinetics and metabolism., Neurology
    Perlis RH et al., 2013, Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder., Pharmacogenomics J
    Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
    Tadori et al., 2011, Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors., Eur. J. Pharmacol.
    Citrome, 2011, Role of sublingual asenapine in treatment of schizophrenia., Neuropsychiatr Dis Treat
    Tsuchimine S et al., 2012, DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study., J Clin Psychopharmacol
    McCracken JT et al., 2014, Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders., Pharmacogenomics J
  • PRAMIPEXOLE   DRD3

    Interaction Score: 3.8

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name Mirapex

    PMIDs:
    18691132 10641988 11752352 19396436 22023785 9638397 9617505 18248314


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • ROPINIROLE   DRD3

    Interaction Score: 1.9

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name ReQuip
    Novel drug target Established target
    Trial Name JZP-7

    PMIDs:
    18691132 10641988 11752352 19557097 19503779


    Sources:
    TdgClinicalTrial TEND TTD

  • CARIPRAZINE   DRD3

    Interaction Score: 0.95

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name cariprazine, RGH-188

    PMIDs:
    23320989


    Sources:
    TdgClinicalTrial TTD

  • PRECLAMOL HYDROCHLORIDE   DRD3

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1256778   DRD3

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORPROTHIXENE   DRD3

    Interaction Score: 0.82

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D3 receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    1830565 17016423 17139284


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • ROTIGOTINE   DRD3

    Interaction Score: 0.57

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name Neupro
    Mechanism of Interaction D2-like dopamine receptor agonist

    PMIDs:
    18691132


    Sources:
    TdgClinicalTrial ChemblInteractions

  • AMISULPRIDE   DRD3

    Interaction Score: 0.53

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name amisulpride,Solian

    PMIDs:
    12404702 11873706 16696579


    Sources:
    TdgClinicalTrial TEND

  • CARIPRAZINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.48

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Mechanism of Interaction Dopamine D3 receptor modulator
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SULPIRIDE   DRD3

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    18973551 19795811 22632094


    Sources:
    DTC

  • QUINPIROLE   DRD3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    21536445


    Sources:
    DTC

  • ETILEVODOPA   DRD3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name etilevodopa, TV-1203
    Mechanism of Interaction Dopamine D3 receptor agonist

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • CHEMBL1256698   DRD3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PRAMIPEXOLE DIHYDROCHLORIDE   DRD3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEXPRAMIPEXOLE   DRD3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name dexpramipexole, KNS-760704
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • APOMORPHINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TALIPEXOLE HYDROCHLORIDE   DRD3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • APOMORPHINE   DRD3

    Interaction Score: 0.27

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name apomorphine HCl,Uprima, Ixense
    Novel drug target Established target
    Trial Name apomorphine hydrochloride,Apokyn, APO-go

    PMIDs:
    11752352 15037665


    Sources:
    TdgClinicalTrial TEND

  • PARDOPRUNOX   DRD3

    Interaction Score: 0.27

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Trial Name pardoprunox, SLV 308
    Novel drug target Established target
    Mechanism of Interaction Dopamine receptors; D2 & D3 partial agonist

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • LEVOMEPROMAZINE   DRD3

    Interaction Score: 0.27

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    15701205


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • PERGOLIDE MESYLATE   DRD3

    Interaction Score: 0.27

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    DTC ChemblInteractions

  • HALOPERIDOL LACTATE   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL1255656   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL1256876   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SARIZOTAN HYDROCHLORIDE   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D3 receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROPINIROLE HYDROCHLORIDE   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HALOPERIDOL DECANOATE   DRD3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ASENAPINE   DRD3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Asenapine
    Novel drug target Established target

    PMIDs:
    18308814 21658377 21655346


    Sources:
    TdgClinicalTrial

  • ZIPRASIDONE   DRD3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17016423 17139284 17848919


    Sources:
    TEND

  • LEVODOPA   DRD3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D3 receptor agonist
    Direct Interaction yes
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    30794329 27779245 9633680 18549347 11978145


    Sources:
    TdgClinicalTrial ChemblInteractions PharmGKB

  • AGROCLAVINE   DRD3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OLANZAPINE PAMOATE   DRD3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ONC-201   DRD3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LOXAPINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL544115   DRD3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BROMOCRIPTINE   DRD3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name bromocriptine mesylate,Cycloset, Ergoset
    Novel drug target Established target

    PMIDs:
    18691132 10641988


    Sources:
    TdgClinicalTrial

  • QUETIAPINE   DRD3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    ligand
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919 25025989 20392299 12544369


    Sources:
    PharmGKB

  • BIFEPRUNOX   DRD3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name bifeprunox, DU127090
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • LOXAPINE   DRD3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DROPERIDOL   DRD3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LOXAPINE SUCCINATE   DRD3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AMOXAPINE   DRD3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    16135699


    Sources:
    ChemblInteractions

  • BROMOCRIPTINE MESYLATE   DRD3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MELEVODOPA   DRD3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name V-1512, CHF-1512,Levomet Complex, Sirio

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • ILOPERIDONE   DRD3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name iloperidone,Fanapt, Fiapta, Zomaril
    Novel drug target Established target

    PMIDs:
    23545936


    Sources:
    TdgClinicalTrial

  • PROMAZINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL284609   DRD3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OLANZAPINE   DRD3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    17848919 11752352 18320559 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • DULOXETINE   DRD3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22249355


    Sources:
    PharmGKB

  • DOPAMINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORPROMAZINE   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    8301582


    Sources:
    ChemblInteractions

  • COCAINE   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • HALOPERIDOL   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inverse agonist (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    16123775 7520908 9536001 19496999 18831971


    Sources:
    ChemblInteractions

  • TRIFLUOPERAZINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • RISPERIDONE   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    19997080 19506579 7520908 7531353


    Sources:
    PharmGKB

  • PAROXETINE   DRD3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22926616


    Sources:
    PharmGKB

  • ERGOLOID MESYLATES   DRD3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine receptor agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PIMOZIDE   DRD3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    8301582


    Sources:
    ChemblInteractions

  • METHAMPHETAMINE   DRD3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21491142


    Sources:
    PharmGKB

  • CLOZAPINE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    21332319 20029384 17848919


    Sources:
    PharmGKB

  • THIORIDAZINE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIORIDAZINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHLORPROMAZINE HYDROCHLORIDE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OLEOYL DOPAMINE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHYLPHENIDATE   DRD3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23856854


    Sources:
    PharmGKB

  • Ensembl: ENSG00000151577

    • Version: 101_38

    Alternate Names:
    DRD3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000151577

    • Version: 26-July-2011

    Alternate Names:
    DRD3 Display Id
    D(3) DOPAMINE RECEPTOR. [SOURCE:UNIPROT/SWISSPROT;ACC:P35462] Description
    ENSG00000151577 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P35462

    • Version: 11-September-2012

    Alternate Names:
    P35462 Uniprot Accession
    D(3) DOPAMINE RECEPTOR Uniprot Protein Name
    ENSG00000151577 Ensembl Gene Id

    Gene Info:
    Interpro Name GPCR, rhodopsin-like, 7TM
    Interpro Acc IPR000276
    Interpro Type Family

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P35462

    • Version: January-2014

    Alternate Names:
    DRD3 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin

    Publications:

  • TEND: P35462

    • Version: 01-August-2011

    Alternate Names:
    P35462 Uniprot Accession
    DRD3 Gene Symbol
    1814 Entrez Gene Id

    Gene Info:
    Target Subclass GPCR
    Transmembrane Helix Count 6
    Target Subclass Rhodopsin

    Publications:

  • PharmGKB: DRD3

    • Version: 18-August-2020

    Alternate Names:
    PA27479 PharmGKB ID

    Gene Info:

    Publications:
    Gupta S et al., 2011, Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings., J Neurovirol
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J

  • DTC: DRD3

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem
    Newman AH et al., 2012, Molecular determinants of selectivity and efficacy at the dopamine D3 receptor., J Med Chem

  • ChemblInteractions: DRD3

    • Version: chembl_23

    Alternate Names:
    DRD3 GENE_SYMBOL
    D(3) dopamine receptor UNIPROT
    Dopamine D3 receptor UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000151577

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000151577 Gene Symbol
    DRD3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • dGene: DRD3

    • Version: 27-Jun-2013

    Alternate Names:
    1814 Gene ID
    D3DR dGene Synonym
    ETM1 dGene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

  • TTD: Dopamine D3 receptor

    • Version: 2020.06.01

    Alternate Names:
    D3R TTD Gene Abbreviation
    T02551 TTD Target ID

    Gene Info:

    Publications:

  • GO: DRD3

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21